Latest Market Data
Refresh
Market Turnover
-






-
-
|
|
|
|
|
|
-
-
-
Loading

VISEN PHARMACEUTICALS - B (2561)

VISEN PHARMA-B (2561)

HK$49.300

+0.400 (+0.82%)

Prev. Close is the most recent non-zero closing value or settlement price.PREV. CLOSE
HK$48.900
Open price is the first traded price of the day. The opening price is reported after 09:20:00 HKT.OPEN
HK$48.900
TURNOVER
HK$1.36M
VOLUME
27.70K
MKT CAP
HK$5.61B
LOT SIZE
100
BID
HK$49.300
ASK
HK$49.320
EPS
-
P/E
-
DIV YIELD
-
INTRA-DAY 52W
High HK$50.500 HK$69.150
Low HK$48.140 HK$39.250
Information is available after the market opens and is delayed by at least 15 minutes.
Updated: 13 Aug 2025 15:59 HKT
  • 1 D
  • 1 M
  • 3 M
  • 6 M
  • YTD
  • 1 Y
  • 2 Y
  • 5 Y
  • 10 Y
1min
5min
15min
Hourly
Created with Highstock 6.2.00.00048.00048.80049.60050.40051.20003K6K10:0011:0012:0013:0014:0015:0016:00Prev. Close
48.900
All charts use the last traded price or closing price.

COMPANY PROFILE

Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares) 113,926,864 (as at 31 Jul 2025)
Industry Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Listing Date 21 Mar 2025
Financial Year Ends -
Chairman Fu Shan
Principal Office Room 1919, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay, Hong Kong
Place of Incorporation Cayman Islands
Listing Category Primary Listing

a. Updating time-lag
The number of issued shares / issued units presented is generally updated within 7 days after the Monthly Returns and Next Day Disclosure Returns published by the listed issuers on the HKEXnews website. Hence, the information presented here may not be the most up-to-date information submitted by the listed issuers as required under the Listing Rules.
b. Rights issues or bonus issues
The number of issued shares / issued units presented here will be adjusted with effect from the ex-date in the event of announced rights issues or announced bonus issues. In this case, both the number of issued shares / issued units before and after the adjustment will be presented.
c. Share splits or share consolidations
The number of issued shares / issued units presented here will be adjusted on the effective date in the event of share splits or share consolidations.
d. Conversion of convertible notes into shares
If the change of the number of issued shares / issued units is due to conversion of convertible bonds, the number of issued shares / issued units presented here may be updated based on the related company announcement.
Updated: 13 Aug 2025 19:05 HKT
* Company profile is provided by Refinitiv.

ENTITLEMENT

Date Announced Ex-Date Details Financial Year End Book Close Date Payment date may be indicative only.Payment Date
Updated:
Dividend details are sourced from Announcement Forms published on HKEXnews